Beam Therapeutics Inc. (BEAM) News & EventsBEAMBeam Therapeutics Inc.

Beam Therapeutics Presents Initial Data on BEAM-301 at ESGCT

Beam Therapeutics announced that the company will present initial data from the ongoing Phase 1/2 clinical trial evaluating BEAM-301 for the treatment of glycogen storage disease type Ia, or GSDIa, at the 33rd Annual Congress of the European Society of Gene and Cell Therapy, or ESGCT, taking place October 27-30, in Hamburg, Germany. BEAM-301 is a liver-targeting lipid-nanoparticle, or LNP, formulation of base editing reagents designed to correct the R83C mutation, one of the most prevalent disease-causing mutations in GSDIa and one that is associated with the most severe form of the disease. As of the June 26, data cutoff, six patients received a single intravenous infusion of BEAM-301, including three patients treated with 20 mg and three patients treated with 40 mg. Median follow-up was 313 days in the 20 mg cohort and 53 days in the 40 mg cohort. One patient in the 40 mg cohort was not evaluable for efficacy as of the data cutoff. BEAM-301 demonstrated an acceptable safety profile that was consistent with LNP-based therapies. All patients experienced at least one treatment-emergent adverse event considered related to BEAM-301. Five serious adverse events were reported and resolved within two to 10 days, including three Grade 3 infusion-related reactions. The use of shorter-acting steroids as premedication, which is typical in this patient population, may have contributed to the Grade 3 IRRs observed. The steroid premedication regimen has since been optimized. All transaminase elevations were transient and resolved without intervention. With the exception of a single Grade 2 elevation in aspartate aminotransferase, all transaminase elevations were Grade 1. No dose-limiting toxicities, treatment discontinuations due to treatment-emergent adverse events, or deaths were reported. Dose-dependent improvements in time to fasting hypoglycemia were observed. At baseline, median TTH was 2.9 hours in the 20 mg cohort and 2.5 hours in the 40 mg cohort. By Day 36, median TTH increased to 4.3 hours in the 20 mg cohort, while both evaluable patients in the 40 mg cohort achieved the protocol-defined maximum controlled fasting duration of greater than or equal to15 hours, consistent with restored endogenous glucose production. Reductions in prescribed daily starch intake were observed following treatment with BEAM-301. Decreases from baseline in prescribed daily starch intake guided by continuous glucose monitoring were 74%, 71%, and 11% in the 20 mg cohort, and 71% and 92% in the 40 mg cohort. Corresponding daily starch doses decreased by 0-4 and 2-4 doses/day in the 20 mg cohort and the 40 mg cohort, respectively. Triglyceride levels were comparable to baseline at last follow-up. Updated data from the ongoing Phase 1/2 trial will be presented during the ESGCT poster session.

Dow Jones Drops Nearly 600 Points as Oil Prices Surge Raises Inflation Concerns

The major averages closed broadly lower, with the Dow Jones losing nearly 600 points as a renewed jump in oil prices and escalating Middle East tensions stoked inflation concerns.The rise in oil prices is particularly problematic coming after Friday's stronger-than-expected August jobs report. The U.S. added 162,000 jobs, nearly three times economists' expectations, pushing markets to increase bets that the Federal Reserve could raise rates at its September 16 meeting. The probability of a hike is now around 60%, while the 10-year Treasury yield has climbed to roughly 4.8%.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:An Amazoncargo plane overshot the runway at Miami International Airport this weekend,Qualcommannounced awith AmazonGE AerospaceConsolidated Precision Products for $11.75BBoston Scientificsaid it isits Q3 and FY26 net sales and adjusted earnings per share guidanceNovartisshares fell after its Phase 3 HARBOR study for DM12. WALL STREET CALLS:Intelto Outperform at Northland after "material" turnaround progressPelotonto Underweight at Morgan StanleyAirbnbto Outperform at Raymond JamesBest Buyto Neutral at DA DavidsonSpaceXwith a Buy at Pivotal Research3. AROUND THE WEB:Netflixplans to report box office grosses for six upcoming films, Variety reportsNvidia-backedFirmus signed a multi-year deal with OpenAI to supply computing capacity to two Malaysian data centers, Reuters reportsAhead of Oura's upcoming IPO filing, Robinhoodhas been listed as an underwriter, WSJ saysNovo Nordiskhas halted two trials testing of ziltivekimab, its experimental heart disease medicine, would help patients with heart failure, Bloomberg reportsThe Independent Communications Authority of South Africa, South Africa's telecommunications regulator, plans to investigate prices charged by providers such as Netflixand Meta'sWhatsApp, Bloomberg reports4. MOVERS:Roivant Sciencesgained in New York after announcing its Phase 3 PHocus clinical trialPharvarisincreased in New York after announcing its CHAPTER-3 Phase 3 studyD-Wave Quantumwas higher afterwith the U.S. Department of CommerceSigma Lithiumfell after a preliminary judicial rulingBeam Therapeuticswas lower after announcing updated clinical data from its5. EARNINGS/GUIDANCE:United Natural Foodsand provided guidance for FY27ABMand raised its outlook for FY26, with CEO Scott Salmirs highlighting "record quarterly revenue, robust EPS growth and substantial cash generation"Solaris Energyraised itsGeneral Millsreaffirmed itsGameStop, with EPS higher year-over-yearINDEXES:The Dow fell 628.18, or 1.18%, to 52,786.07, the Nasdaq lost 85.58, or 0.32%, to 26,421.41, and the S&P 500 declined 45.08, or 0.58%, to 7,673.52.

Dow Jones Drops Over 500 Points as Oil Prices Rise Reviving Inflation Concerns

The major averages were broadly lower near noon, with the Dow Jones losing over 500 points as a renewed jump in oil prices and escalating Middle East tensions revive inflation concerns.The rise in oil prices is particularly problematic coming after Friday's stronger-than-expected August jobs report. The U.S. added 162,000 jobs, nearly three times economists' expectations, pushing markets to increase bets that the Federal Reserve could raise rates at its September 16 meeting. The probability of a hike is now around 60%, while the 10-year Treasury yield has climbed to roughly 4.8%.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:An Amazoncargo plane overshot the runway at Miami International Airport this weekend,Qualcommannounced awith AmazonGE AerospaceConsolidated Precision Products for $11.75BBoston Scientificsaid it isits Q3 and FY26 net sales and adjusted earnings per share guidanceNovartisshares fell after its Phase 3 HARBOR study for DM12. WALL STREET CALLS:Intelto Outperform at Northland after "material" turnaround progressPelotonto Underweight at Morgan StanleyAirbnbto Outperform at Raymond JamesBest Buyto Neutral at DA DavidsonSpaceXwith a Buy at Pivotal Research3. AROUND THE WEB:Nvidia-backedFirmus signed a multi-year deal with OpenAI to supply computing capacity to two Malaysian data centers, Reuters reportsAhead of Oura's upcoming IPO filing, Robinhoodhas been listed as an underwriter, WSJ saysNovo Nordiskhas halted two trials testing of ziltivekimab, its experimental heart disease medicine, would help patients with heart failure, Bloomberg reportsAir Cairo is set to purchase 15 AirbusA320 family jets, with the deal expected to be finalized as soon as this week, Bloomberg saysThe Independent Communications Authority of South Africa, South Africa's telecommunications regulator, plans to investigate prices charged by providers such as Netflixand Meta'sWhatsApp, Bloomberg reports4. MOVERS:Roivant Sciencesgains in New York after announcing its Phase 3 PHocus clinical trialPharvarisincreases in New York after announcing its CHAPTER-3 Phase 3 studyD-Wave Quantumhigher afterwith the U.S. Department of CommerceSigma Lithiumfalls after a preliminary judicial rulingBeam Therapeuticslower after announcingfrom its Phase 1/2 trial evaluating BEAM-3025. EARNINGS/GUIDANCE:United Natural Foodsand provided guidance for FY27ABMand raised its outlook for FY26, with CEO Scott Salmirs highlighting "record quarterly revenue, robust EPS growth and substantial cash generation"Solaris Energyfor Q3 and Q4General Millsfor FY27GameStop, with EPS higher year-over-yearINDEXES:Near midday, the Dow was down 562.84, or 1.05%, to 52,851.41, the Nasdaq was down 23.20, or 0.09%, to 26,483.79, and the S&P 500 was down 27.48, or 0.36%, to 7,691.12.